With its clinical and medical experts, the team of Innovative Molecules
dedicates its work to
patients suffering from
herpes-mediated diseases.
While there has not been much medical improvement in the treatment of Herpes simplex disease
over decades, the team aims
to translate novel scientific findings into best-in-class therapies to improve current
therapeutic regimens and helps
patients in time of need.
Founded in 2016, Innovative Molecules is a German biotech focused on discovery, development
and commercialization of
novel agents in the field of herpes-mediated diseases.
The team has strong expertise in development and commercialization of medicines to help
patients with debilitating
disease around the globe.
Former Managing Director at
MYR GmbH (now part of Gilead
Sciences) and CCO
Successfully managed a range of product launches of biotech and pharma products
Founder and former CFO at
Phenex Pharmaceuticals
Track record in transactions
incl. major licensing & assets deals
Co-managed dual IPO at
NASDAQ & Frankfurt Stock exchange
Founder and former Chief
Medical Officer at MYR GmbH
Held drug development
positions at various major
pharmaceutical organizations
Key driver of development for
HepD drug Hepcludex
Founder & CSO
at Innovative Molecules
Track record in discovery
research and preclinical
development in academia
and industry
Discovered multiple antivirals incl. letermovir, pritelivir and IM-250